CLDX Q4 2025 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$75,000-93.6% YoY

Gross Profit

$75,000100.0% margin

Operating Income

-$87M-116249.3% margin

Net Income

-$81M-108480.0% margin

EPS (Diluted)

$-1.23

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$64M

Free Cash Flow

-$65M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$583M

Total Liabilities

$56M

Stockholders' Equity

$527M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75,000	$1M	-93.6%
Gross Profit	$75,000	$356,000	-78.9%
Operating Income	-$87M	-$56M	-55.6%
Net Income	-$81M	-$47M	-72.8%